NO20074635L - Anvendelse av et influensa virus som en olje-i-vann emulsjon adjuvans for a indusere CD4 T-celle og/eller forbedret B-hukommelse celle respons - Google Patents

Anvendelse av et influensa virus som en olje-i-vann emulsjon adjuvans for a indusere CD4 T-celle og/eller forbedret B-hukommelse celle respons

Info

Publication number
NO20074635L
NO20074635L NO20074635A NO20074635A NO20074635L NO 20074635 L NO20074635 L NO 20074635L NO 20074635 A NO20074635 A NO 20074635A NO 20074635 A NO20074635 A NO 20074635A NO 20074635 L NO20074635 L NO 20074635L
Authority
NO
Norway
Prior art keywords
oil
water emulsion
induce
enhanced
influenza virus
Prior art date
Application number
NO20074635A
Other languages
English (en)
Norwegian (no)
Inventor
Jean Stephenne
Emmanuel Jules Hanon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36441219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074635(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0505998A external-priority patent/GB0505998D0/en
Priority claimed from GB0505989A external-priority patent/GB0505989D0/en
Priority claimed from GB0506004A external-priority patent/GB0506004D0/en
Priority claimed from GB0506000A external-priority patent/GB0506000D0/en
Priority claimed from GB0506001A external-priority patent/GB0506001D0/en
Priority claimed from GB0510589A external-priority patent/GB0510589D0/en
Priority claimed from GB0510591A external-priority patent/GB0510591D0/en
Priority claimed from GB0510593A external-priority patent/GB0510593D0/en
Priority claimed from GB0510598A external-priority patent/GB0510598D0/en
Priority claimed from GB0510596A external-priority patent/GB0510596D0/en
Priority claimed from GB0603790A external-priority patent/GB0603790D0/en
Priority claimed from GB0603788A external-priority patent/GB0603788D0/en
Priority claimed from GB0603789A external-priority patent/GB0603789D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20074635L publication Critical patent/NO20074635L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20074635A 2005-03-23 2007-09-12 Anvendelse av et influensa virus som en olje-i-vann emulsjon adjuvans for a indusere CD4 T-celle og/eller forbedret B-hukommelse celle respons NO20074635L (no)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
GB0505989A GB0505989D0 (en) 2005-03-23 2005-03-23 Compositions
GB0506004A GB0506004D0 (en) 2005-03-23 2005-03-23 Compositions
GB0506000A GB0506000D0 (en) 2005-03-23 2005-03-23 Novel use
GB0506001A GB0506001D0 (en) 2005-03-23 2005-03-23 Novel use
GB0505998A GB0505998D0 (en) 2005-03-23 2005-03-23 Novel compositions
GB0510591A GB0510591D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510589A GB0510589D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510593A GB0510593D0 (en) 2005-05-24 2005-05-24 Novel compositions
GB0510598A GB0510598D0 (en) 2005-05-24 2005-05-24 Composition
GB0510596A GB0510596D0 (en) 2005-05-24 2005-05-24 Composition
GB0603790A GB0603790D0 (en) 2006-02-24 2006-02-24 Composition
GB0603788A GB0603788D0 (en) 2006-02-24 2006-02-24 Novel composition
GB0603789A GB0603789D0 (en) 2006-02-24 2006-02-24 Novel use
PCT/EP2006/002836 WO2006100109A1 (en) 2005-03-23 2006-03-21 Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response

Publications (1)

Publication Number Publication Date
NO20074635L true NO20074635L (no) 2007-12-19

Family

ID=36441219

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20074638A NO20074638L (no) 2005-03-23 2007-09-12 Ny sammensetning
NO20074635A NO20074635L (no) 2005-03-23 2007-09-12 Anvendelse av et influensa virus som en olje-i-vann emulsjon adjuvans for a indusere CD4 T-celle og/eller forbedret B-hukommelse celle respons
NO20074930A NO20074930L (no) 2005-03-23 2007-09-28 Blanding

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20074638A NO20074638L (no) 2005-03-23 2007-09-12 Ny sammensetning

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20074930A NO20074930L (no) 2005-03-23 2007-09-28 Blanding

Country Status (24)

Country Link
US (5) US20080171063A1 (es)
EP (4) EP1863529A1 (es)
JP (4) JP5869744B2 (es)
KR (5) KR20070116650A (es)
AR (3) AR054020A1 (es)
AU (3) AU2006226458B2 (es)
CA (3) CA2602456A1 (es)
CY (1) CY1117874T1 (es)
DK (1) DK1861120T3 (es)
EA (3) EA011419B1 (es)
ES (1) ES2585810T3 (es)
HR (1) HRP20160816T1 (es)
HU (1) HUE027837T2 (es)
IL (3) IL185901A0 (es)
MA (3) MA30298B1 (es)
MX (3) MX2007011756A (es)
NO (3) NO20074638L (es)
NZ (2) NZ561823A (es)
PE (3) PE20061300A1 (es)
PL (1) PL1861120T3 (es)
PT (1) PT1861120T (es)
SI (1) SI1861120T1 (es)
TW (3) TW200700079A (es)
WO (3) WO2006100111A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228454T3 (es) * 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
NZ561823A (en) * 2005-03-23 2010-04-30 Glaxosmithkline Biolog Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514839A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
WO2007052061A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
ATE513561T1 (de) 2005-11-04 2011-07-15 Novartis Vaccines & Diagnostic Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien
DK2368572T3 (da) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
JP2009534303A (ja) * 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
WO2007144772A2 (en) 2006-06-15 2007-12-21 Novartis Ag Adjuvant-sparing multi-dose influenza vaccination regimen
PT2043682E (pt) * 2006-07-17 2014-07-11 Glaxosmithkline Biolog Sa Vacina da influenza
CA2583555C (en) * 2006-07-17 2020-01-07 Glaxosmithkline Biologicals S.A. Influenza vaccine
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
EP2086582B1 (en) * 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
BRPI0717219B8 (pt) * 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
EP1923070A1 (en) * 2006-11-15 2008-05-21 Intervet International BV Vaccine for vaccinating feline against influenza virus
NZ577405A (en) * 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP1938835A1 (en) * 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
MX2009008926A (es) * 2007-02-23 2009-09-14 Baylor Res Inst Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EP2195019A4 (en) * 2007-10-12 2012-02-15 Csl Ltd METHOD FOR TRIGGERING AN IMMUNE RESPONSE AGAINST THE PANDEMIC INFLUENZA VIRUS
EP2462949A3 (en) 2007-10-19 2012-09-05 Novartis AG Meningococcal vaccine formulations
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP2011506290A (ja) * 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ組成物
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
EP2889042A3 (en) * 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
CN104080475A (zh) 2008-04-18 2014-10-01 法克斯因内特公司 鞭毛蛋白的缺失突变体以及使用方法
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
WO2009156852A1 (en) 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
EP2942062A1 (en) 2009-02-10 2015-11-11 Novartis AG Influenza vaccine regimens for pandemic-associated strains
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
WO2010148496A1 (en) * 2009-06-22 2010-12-29 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
EP2289575B1 (de) * 2009-08-06 2017-07-05 Biotronik VI Patent AG Medizinisches Implantat enthaltend eine antioxidative Substanz
CN102573802A (zh) * 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
EP2308506A1 (en) * 2009-10-02 2011-04-13 Mucosis B.V. Adjuvanted intranasal vaccine formulations
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
AU2013202690B2 (en) * 2009-12-03 2016-02-11 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
EP2601933B1 (en) * 2009-12-03 2015-10-07 Novartis AG Hydrophilic filtration during manufacture of vaccine adjuvants
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
FI2638895T3 (fi) 2009-12-03 2024-06-20 Seqirus Uk Ltd Ainesosien kierrätys emulsioiden homogenisoinnin aikana
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
BR112012013426B8 (pt) * 2009-12-03 2021-05-25 Novartis Ag métodos para a fabricação de uma emulsão de óleo-em-água, para preparar uma composição de vacina e para preparar um kit de vacina
US20130183350A1 (en) * 2009-12-22 2013-07-18 Kevin Harper Immunogenic compositions
JP2013516469A (ja) * 2010-01-06 2013-05-13 ヴァクシネイト コーポレイション 高齢者に保護免疫を提供するための方法及び組成物
WO2011088451A1 (en) * 2010-01-15 2011-07-21 Novavax, Inc. Uses of influenza virus-like particles (vlps) for characterization of neuraminidase and hemagglutinin activity
RU2527688C2 (ru) * 2010-02-27 2014-09-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностого антигена н1n1 и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена н1n1
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009671D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) * 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
AU2013367751B2 (en) * 2012-12-28 2018-02-08 Japan As Represented By Director General Of National Institute Of Infectious Diseases Nasal influenza vaccine composition
JP2016521282A (ja) * 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
CN104436157A (zh) * 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) * 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
US20170304429A1 (en) * 2014-09-26 2017-10-26 Seqirus UK Limited Vaccination of immunocompromised subjects
US20200306364A1 (en) * 2017-11-30 2020-10-01 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
CA3127639A1 (en) 2019-01-30 2020-08-06 Glaxosmithkline Biologicals Sa Oil/surfactant mixtures for self-emulsification
WO2021123117A1 (de) * 2019-12-20 2021-06-24 Fresenius Kabi Austria Gmbh Verfahren zur herstellung von öl-in-wasser-emulsionen
RU2741003C1 (ru) * 2020-03-27 2021-01-22 Евгений Дмитриевич Некрасов Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов
US20230256090A1 (en) 2020-06-29 2023-08-17 Glaxosmithkline Biologicals Sa Adjuvants
CA3190375A1 (en) 2020-08-24 2022-03-03 Natalie ANOSOVA Covid-19 vaccines with tocopherol-containing squalene emulsion adjuvants
IL300632A (en) 2020-08-24 2023-04-01 Sanofi Pasteur Inc Vaccines against SARS-COV-2 infections
KR102270165B1 (ko) 2020-10-22 2021-06-28 한국화학연구원 세정제 조성물
US20240165224A1 (en) 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4362974A1 (en) 2021-06-28 2024-05-08 GlaxoSmithKline Biologicals S.A. Novel influenza antigens
RU2766292C1 (ru) * 2021-08-05 2022-03-14 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) Состав вакцины против covid-19
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095974A (en) * 1961-10-27 1963-07-02 Anthony R Perini Collapsible book rack
US4047869A (en) * 1973-02-23 1977-09-13 Mulvany Jr R F Apparatus for forming plastic articles
FR2333610A1 (fr) * 1975-12-03 1977-07-01 Zhdanovsky Z Tyazhelogo Mash Bande-electrode a ame en poudre pour rechargement a l'aide d'un alliage resistant a l'usure
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
ES2068989T3 (es) * 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
US5092235A (en) 1989-05-24 1992-03-03 Tektronix, Inc. Pressure fixing and developing apparatus
JPH0832638B2 (ja) * 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
WO1991013261A1 (en) 1990-03-02 1991-09-05 Experimentalny Nauchno-Issledovatelsky Institut Metallorezhuschikh Stankov Digital servo drive
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
CA2156525A1 (en) 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
WO1995014026A1 (en) 1993-11-17 1995-05-26 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
BR9506885A (pt) 1994-02-24 1997-08-19 Micro Pak Inc Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
JP4426091B2 (ja) * 1997-09-05 2010-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンを含有する水中油型エマルション
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
HUP0101047A3 (en) * 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions
US6838269B1 (en) * 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
ES2296390T3 (es) 1998-05-07 2008-04-16 Corixa Corporation Composicion coadyuvante y procedimiento para su uso.
SK18602000A3 (sk) 1998-06-08 2001-07-10 Sca Emballage France Obal umožňujúci rýchle vyrovnanie
ES2284275T3 (es) 1998-06-30 2007-11-01 Om Pharma Nuevos pseudodipeptidos acilados, su procedimientos de preparacion y las composiciones farmaceuticas que los incluyen.
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
EP1574210B1 (en) 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Microemulsions with adsorbed macromolecules
FR2796290B1 (fr) 1999-07-16 2001-09-14 Cross Site Technologies Seringue sans aiguille fonctionnant avec un generateur d'onde de choc a travers une paroi
FR2796291B1 (fr) 1999-07-16 2001-09-21 Cross Site Technologies Seringue sans aiguille munie d'un systeme de declenchement piezo-electrique
FR2796289B1 (fr) 1999-07-16 2001-08-10 Cross Site Technologies Seringue sans aiguille avec injecteur a elements superposes
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2800619B1 (fr) 1999-11-05 2002-02-08 Cross Site Technologies Seringue sans aiguille avec un moyen de poussee temporairement retenu
FR2802102B1 (fr) 1999-12-08 2002-07-12 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un tube d'ejection a section constante
FR2802103B1 (fr) 1999-12-08 2003-10-03 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec entrainement du principe actif par effet tube a choc
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
FR2802820B1 (fr) 1999-12-27 2002-10-18 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par effet tube a choc, avec maintien prealable du principe actif sur le cote
AP2002002592A0 (en) 2000-01-31 2002-09-30 Smithkline Beecham Biolog Vaccine for the prophylactic or therapeutic immunization against HIV.
FR2804329B1 (fr) 2000-02-02 2002-12-13 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un opercule contenant le principe actif
FR2804869B1 (fr) 2000-02-11 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille pour l'injection d'un liquide contenu dans une ampoule pre-remplie
FR2805749B1 (fr) 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille a deux niveaux de vitesse d'injection
FR2807946B1 (fr) 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
FR2809626B1 (fr) 2000-05-30 2003-03-07 Poudres & Explosifs Ste Nale Seringue sans aiguille avec membrane d'isolation d'un ejecteur multiconduit
FR2810554B1 (fr) 2000-06-22 2003-05-16 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un reservoir modulable
FR2812202B1 (fr) 2000-07-28 2002-09-13 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par mise en compression du reservoir contenant le principe actif liquide
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
EP1201250A1 (en) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
US20040071734A1 (en) * 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
CA2478930A1 (en) * 2002-04-01 2003-10-16 Euro-Celtique, S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
EP1594536B1 (en) 2003-01-30 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Adjuvanted influenza vaccine
CA2559371C (en) * 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
NZ561823A (en) * 2005-03-23 2010-04-30 Glaxosmithkline Biolog Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
PT2043682E (pt) * 2006-07-17 2014-07-11 Glaxosmithkline Biolog Sa Vacina da influenza
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
JP2011506290A (ja) * 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ組成物

Also Published As

Publication number Publication date
NO20074638L (no) 2007-12-19
WO2006100110A1 (en) 2006-09-28
KR20070116650A (ko) 2007-12-10
WO2006100111A1 (en) 2006-09-28
TW200700079A (en) 2007-01-01
PL1861120T3 (pl) 2016-11-30
IL185901A0 (en) 2008-01-06
JP5869744B2 (ja) 2016-02-24
IL185897A0 (en) 2008-01-06
AR054020A1 (es) 2007-05-30
KR101916787B1 (ko) 2019-01-24
CA2601022C (en) 2023-03-07
US20110287054A1 (en) 2011-11-24
IL185906A0 (en) 2008-01-06
CA2601022A1 (en) 2006-09-28
EP2397153A1 (en) 2011-12-21
DK1861120T3 (en) 2016-07-25
EA200701787A1 (ru) 2008-08-29
KR20070116651A (ko) 2007-12-10
US20080171063A1 (en) 2008-07-17
US20080181911A1 (en) 2008-07-31
EA011393B1 (ru) 2009-02-27
AU2006226543A1 (en) 2006-09-28
EP1863529A1 (en) 2007-12-12
JP2008534467A (ja) 2008-08-28
HUE027837T2 (en) 2016-11-28
KR20160064249A (ko) 2016-06-07
NO20074930L (no) 2007-12-07
EP1861120B1 (en) 2016-05-25
CY1117874T1 (el) 2017-05-17
AU2006226458B2 (en) 2012-08-30
CA2603180C (en) 2015-10-13
KR20140004815A (ko) 2014-01-13
SI1861120T1 (sl) 2016-09-30
IL185897A (en) 2015-11-30
NZ561823A (en) 2010-04-30
EA200701785A1 (ru) 2008-04-28
ES2585810T3 (es) 2016-10-10
HRP20160816T1 (hr) 2016-08-12
JP2008534465A (ja) 2008-08-28
US20140363474A1 (en) 2014-12-11
MA30298B1 (fr) 2009-04-01
CA2602456A1 (en) 2006-09-28
AU2006226543B2 (en) 2011-10-06
PE20061387A1 (es) 2007-01-19
US20090081253A1 (en) 2009-03-26
EA200701786A1 (ru) 2008-04-28
MA29342B1 (fr) 2008-03-03
PE20061300A1 (es) 2006-12-23
EP1861120A1 (en) 2007-12-05
AU2006226458A1 (en) 2006-09-28
AR053833A1 (es) 2007-05-23
JP2008534466A (ja) 2008-08-28
TW200700078A (en) 2007-01-01
MX2007011775A (es) 2008-03-11
JP2014129359A (ja) 2014-07-10
US9730999B2 (en) 2017-08-15
KR20070116652A (ko) 2007-12-10
MA29715B1 (fr) 2008-09-01
NZ561822A (en) 2010-04-30
EP1861122A1 (en) 2007-12-05
TW200722101A (en) 2007-06-16
EA011419B1 (ru) 2009-02-27
JP5770414B2 (ja) 2015-08-26
CA2603180A1 (en) 2006-09-28
PT1861120T (pt) 2016-08-18
MX2007011756A (es) 2008-03-11
PE20061428A1 (es) 2007-01-16
AU2006226459A1 (en) 2006-09-28
AR052625A1 (es) 2007-03-21
WO2006100109A1 (en) 2006-09-28
MX2007011748A (es) 2008-03-11

Similar Documents

Publication Publication Date Title
NO20074635L (no) Anvendelse av et influensa virus som en olje-i-vann emulsjon adjuvans for a indusere CD4 T-celle og/eller forbedret B-hukommelse celle respons
Ko et al. Immunology and efficacy of MF59-adjuvanted vaccines
NO20090062L (no) Influensavaksine
Garçon et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
Didierlaurent et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Parodi et al. Inactivated influenza vaccines: recent progress and implications for the elderly
Honda-Okubo et al. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses
Alving et al. Adjuvants for human vaccines
Coler et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines
Mount et al. Combination of adjuvants: the future of vaccine design
Rosenkrands et al. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes
Iyer et al. Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants
AR053360A1 (es) Formulaciones novedosas de vacunas
BRPI0621886A8 (pt) composição de vacina contra influenza monovalente, kit, método para a produção de uma composição de vacina contra influenza para uma situação pandêmica ou uma situação pré-pandêmica, e, usos de um antígeno de vírus da influenza ou preparação antigênica do mesmo e de um adjuvante em emulsão óleo-em-água, de um antígeno de vírus da influenza pandêmica ou preparação antigênica do antígeno de hemaglutinina do vírus da influenza, de um vírus da influenza pandêmica ou preparação antigênica do mesmo, e de um adjuvante em emulsão óleo-em-água e de um antígeno ou preparação antigênica de uma primeira cepa de influenza
NO20091022L (no) Vaksine omfattende en olje i vann emulsjons-adjuvant
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
Miyaki et al. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations
van de Sandt et al. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine
Sisteré-Oró et al. Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
Potter et al. Effect of priming on subsequent response to inactivated influenza vaccine
BRPI0609516B8 (pt) uso de um vírus de influenza ou preparação antigênica do mesmo
UY29428A1 (es) Fformulaciones de vacuna contra la gripe, sus usos en medicina y procedimientos de preparación
UY29429A1 (es) Composición inmunogénica que contiene virus de la gripe o preparación antígena del mismo, sus usos y procedimientos de preparación.
SG160386A1 (en) Novel composition
SG139618A1 (en) Influenza vaccine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application